Functional characterization of a novel somatic oncogenic mutation of PIK3CB
Andrew Whale(Karus Therapeutics (United Kingdom)), Stephen J. Shuttleworth(Karus Therapeutics (United Kingdom))
Cited by 44
Related Papers
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
|Current Medicinal Chemistry|2011|103